Publication: Lung Cancer with Brain Metastases Treated with Radiotherapy Followed by Bevacizumab Maintenance: A Case Report
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Nepal Medical Association
Abstract
Abstract
Brain metastases in a patient with non-small cell lung cancer carry a grave prognosis. Without effective interventions, the average survival rate is 6 months. Here, we present a case of a 59-year-old male with non-small cell lung cancer and multiple brain metastases treated with radiotherapy followed by bevacizumab maintenance with prolonged survival. There are limited studies establishing the efficiency and toxicity profile of anti-vascular endothelial growth factors for brain metastases. This reported case had a remarkable response with marked clinical and radiological improvement along with a tolerable toxicity profile. Showing the extent of effectiveness and efficacy of anti-vascular endothelial growth factor agents in the case of lung cancer with brain metastases is the main motto of our study.
Description
Sajjad Ahmed Khan
Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal
Sakshyam Gautam
Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal
Sulav Sapkota
Department of Medical Oncology, Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal
Keywords
Bevacizumab, Brain metastases, Radiotherapy